A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Completed

Plain-English translation of NCT03439280 on ClinicalTrials.gov ↗ · Source last updated February 2023 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

Trial locations(7 sites)

United States

City of Hope - Duarte, Duarte, California

Washington University School of Medicine, St Louis, Missouri

Mount Sinai Hospital-The Donald H. Ruttenberg Cancer Treatment Center, New York, New York

Weill Cornell Medical Center, Div. of Hematology Medical Oncology, New York, New York

Oregon Health & Science University Knight Cancer Institute, Portland, Oregon